Aveanna Healthcare Holdings (AVAH) Lifted Its 2026 Outlook, Is The Stock Now Pricey?

Aveanna Healthcare Holdings (AVAH) is back in focus after reporting second quarter earnings and raising its full year 2026 revenue outlook, tying the update to operational gains across its core home care segments.

See our latest analysis for Aveanna Healthcare Holdings.

The strong 1 day share price return of 9.12% after the results, alongside a 60% 90 day share price return and a very large 3 year total shareholder return, suggests momentum around Aveanna Healthcare Holdings is building as investors reassess its risk and growth profile.

If Aveanna’s earnings update has you rethinking healthcare exposure, it can help to widen your view and see what else is moving in related areas through 42 healthcare AI stocks

Aveanna Healthcare Holdings now sits close to its analyst price target after this sharp run, which raises a simple point: Are traders just crowding into a hot stock, or is the share price finally catching up with the business?

Most Popular Narrative: 23.8% Overvalued

The most widely followed narrative puts Aveanna Healthcare Holdings' fair value at $9.95, well below the recent $12.32 close. This frames today’s debate around how much good news is already reflected in the price.

Accelerating adoption of home-based healthcare and increasing patient preference for in-home care are driving strong and sustained demand for Aveanna's services, which management repeatedly noted remains robust and outstrips the company's current capacity, supporting the potential for significant future revenue growth as the company hires and retains more caregivers.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative still points to upside in revenue yet a lower fair value than the market price? The answer sits in how future margins, earnings levels, and valuation multiples are modeled together. The full breakdown shows exactly which assumptions have the most impact, and how they interact over time.

Result: Fair Value of $9.95 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to factor in risks for Aveanna Healthcare Holdings, including heavy reliance on Medicaid and Medicare funding, as well as the company’s sizeable US$1.47b variable rate debt load.

Find out about the key risks to this Aveanna Healthcare Holdings narrative.

Another View on Aveanna Healthcare Holdings Valuation

The analyst narrative flags Aveanna Healthcare Holdings as 23.8% overvalued against a $9.95 fair value. Yet our DCF model points the other way. On that view, the stock at $12.32 trades around 56% below an estimated value of $27.87. Which framework do you think fits your assumptions better?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Sentiment around Aveanna Healthcare Holdings is clearly mixed, with both real concerns and genuine optimism in play. Act quickly and review the full picture for yourself through 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Aveanna Healthcare Holdings?

If Aveanna's story has sharpened your focus, do not stop here. Broaden your watchlist now and give yourself more options before the next move arrives.

• Target potential mispricings by scanning 52 high quality undervalued stocks that combine quality fundamentals with room for a re rating.
• Prioritise resilience by reviewing 80 resilient stocks with low risk scores that score well on stability and downside protection.
• Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com